The main research trends for immunotherapy of castration-resistant prostate cancer are membrane antigen expression, checkpoints T-lymphocyte-associated protein 4 (CTLA4) blockade, radium-223, and vaccines, and the refinement of establishing organoid models might fuel castration-resistant prostate cancer immunotherapy research in the ongoing development. The gene discussed is CTLA4; the disease is Familial prostate cancer.